CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2017--
Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced that management will
participate in two upcoming investor conferences:
Canaccord Genuity Rare Disease and BioPharma 1x1 Day on Tuesday,
February 7, 2017 in New York, NY
6th Annual Leerink Partners Global Healthcare Conference on
Wednesday, February 15, 2017 in New York, NY; presentation at 11:00
Live audio webcast of the Leerink presentation be available under the
“Investors and Media” section of Seres’ website. A replay of the
presentation will become available approximately one hour after the
event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. The Phase 2
study of Seres' program SER-109 has been completed in multiply recurrent C.
difficile infection. Seres' second clinical candidate, SER-287,
is being evaluated in a Phase 1b study in patients with mild-to-moderate
ulcerative colitis (UC). Seres is also developing SER-262, the first
ever synthetic microbiome therapeutic candidate, in a Phase 1b study in
patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170203005081/en/
Source: Seres Therapeutics Inc.
Carlo Tanzi, Ph.D., 617-203-3467
Investor Relations and Corporate Communications